Cargando…
Association between proton pump inhibitor use and the risk of pancreatic cancer: A Korean nationwide cohort study
PURPOSE: Proton pump inhibitor (PPI) therapy causes hypergastrinemia, which could promote the development and progression of pancreatic cancer. Accordingly, this study aimed to investigate the association between PPI exposure and the risk of pancreatic cancer. METHODS: We conducted a twelve-year lon...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6135510/ https://www.ncbi.nlm.nih.gov/pubmed/30208110 http://dx.doi.org/10.1371/journal.pone.0203918 |
_version_ | 1783354840002330624 |
---|---|
author | Hwang, In Cheol Chang, Jooyoung Park, Sang Min |
author_facet | Hwang, In Cheol Chang, Jooyoung Park, Sang Min |
author_sort | Hwang, In Cheol |
collection | PubMed |
description | PURPOSE: Proton pump inhibitor (PPI) therapy causes hypergastrinemia, which could promote the development and progression of pancreatic cancer. Accordingly, this study aimed to investigate the association between PPI exposure and the risk of pancreatic cancer. METHODS: We conducted a twelve-year longitudinal population-based study (2002–2013) using the Korean National Health Insurance Corporation claims database merged with national health examination data. The study cohort included 453,655 cancer-free individuals in January 2007 (index date). Incident pancreatic cancer was assessed throughout follow up until December 2013. The exposure to PPIs before the index date was assessed using a standardized Defined Daily Dose (DDD) system. We calculated the hazard ratios (HRs) and their 95% confidence intervals (CIs) for pancreatic cancer risk associated with cumulative PPI use using Cox proportional hazard regression models. RESULTS: There were 3,086 cases of pancreatic cancer during the period of 2,920,000 person-years. PPI users exceeding 60 DDDs were at a higher risk of pancreatic cancer compared with non-users (HR, 1.34; 95% CI, 1.04–1.72). Subgroup analyses revealed that a significant association existed between PPI use and pancreatic cancer in low risk groups including individuals who were female, engaged in healthy lifestyle habits, and had no history of diabetes or chronic pancreatitis. CONCLUSION: Exposure to PPI appears to increase the risk of pancreatic cancer, independent of conventional risk factors. |
format | Online Article Text |
id | pubmed-6135510 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-61355102018-09-27 Association between proton pump inhibitor use and the risk of pancreatic cancer: A Korean nationwide cohort study Hwang, In Cheol Chang, Jooyoung Park, Sang Min PLoS One Research Article PURPOSE: Proton pump inhibitor (PPI) therapy causes hypergastrinemia, which could promote the development and progression of pancreatic cancer. Accordingly, this study aimed to investigate the association between PPI exposure and the risk of pancreatic cancer. METHODS: We conducted a twelve-year longitudinal population-based study (2002–2013) using the Korean National Health Insurance Corporation claims database merged with national health examination data. The study cohort included 453,655 cancer-free individuals in January 2007 (index date). Incident pancreatic cancer was assessed throughout follow up until December 2013. The exposure to PPIs before the index date was assessed using a standardized Defined Daily Dose (DDD) system. We calculated the hazard ratios (HRs) and their 95% confidence intervals (CIs) for pancreatic cancer risk associated with cumulative PPI use using Cox proportional hazard regression models. RESULTS: There were 3,086 cases of pancreatic cancer during the period of 2,920,000 person-years. PPI users exceeding 60 DDDs were at a higher risk of pancreatic cancer compared with non-users (HR, 1.34; 95% CI, 1.04–1.72). Subgroup analyses revealed that a significant association existed between PPI use and pancreatic cancer in low risk groups including individuals who were female, engaged in healthy lifestyle habits, and had no history of diabetes or chronic pancreatitis. CONCLUSION: Exposure to PPI appears to increase the risk of pancreatic cancer, independent of conventional risk factors. Public Library of Science 2018-09-12 /pmc/articles/PMC6135510/ /pubmed/30208110 http://dx.doi.org/10.1371/journal.pone.0203918 Text en © 2018 Hwang et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Hwang, In Cheol Chang, Jooyoung Park, Sang Min Association between proton pump inhibitor use and the risk of pancreatic cancer: A Korean nationwide cohort study |
title | Association between proton pump inhibitor use and the risk of pancreatic cancer: A Korean nationwide cohort study |
title_full | Association between proton pump inhibitor use and the risk of pancreatic cancer: A Korean nationwide cohort study |
title_fullStr | Association between proton pump inhibitor use and the risk of pancreatic cancer: A Korean nationwide cohort study |
title_full_unstemmed | Association between proton pump inhibitor use and the risk of pancreatic cancer: A Korean nationwide cohort study |
title_short | Association between proton pump inhibitor use and the risk of pancreatic cancer: A Korean nationwide cohort study |
title_sort | association between proton pump inhibitor use and the risk of pancreatic cancer: a korean nationwide cohort study |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6135510/ https://www.ncbi.nlm.nih.gov/pubmed/30208110 http://dx.doi.org/10.1371/journal.pone.0203918 |
work_keys_str_mv | AT hwangincheol associationbetweenprotonpumpinhibitoruseandtheriskofpancreaticcancerakoreannationwidecohortstudy AT changjooyoung associationbetweenprotonpumpinhibitoruseandtheriskofpancreaticcancerakoreannationwidecohortstudy AT parksangmin associationbetweenprotonpumpinhibitoruseandtheriskofpancreaticcancerakoreannationwidecohortstudy |